

STATEMENT OF PURPOSE

RS26613

The purpose of this legislation is to create co-insurance parity for cancer treatment patient cost regardless of treatment being intravenously administered, injected, or orally taken. The legislation directs the Department of Insurance to ensure state regulated health plans, when anti-cancer medication is covered by a health plan, to provide patients access to orally administered anti-cancer medications at a co-insurance rate no more than the cost to access injected or intravenously administered medication.

FISCAL NOTE

There is no fiscal impact to the state general fund because this legislation affects patients' private out-of-pocket expenses. There is no new required administration by state or local government agencies.

Contact:

Senator Lori Den Hartog

(208) 332-1000

Representative John Vander Woude

(208) 332-1000

DISCLAIMER: This statement of purpose and fiscal note are a mere attachment to this bill and prepared by a proponent of the bill. It is neither intended as an expression of legislative intent nor intended for any use outside of the legislative process, including judicial review (Joint Rule 18).